Proteasome 20S subunit beta type-1 and Proteasome 20S subunit beta type-2 (PSMB1 and PSMB2)

The proteasome beta 1 and beta 2 catalytic sites are essential enzymatic components of the 20S core particle within the 26S proteasome complex, which serves as the primary machinery for regulated protein degradation in eukaryotic cells (UniProt P20618, P49721). The beta 1 subunit (PSMB1) provides caspase-like activity, preferentially cleaving peptide bonds after acidic amino acid residues, while the beta 2 subunit (PSMB2) provides trypsin-like activity, cleaving after basic residues (Groll et al., 1997). These subunits, along with the beta 5 subunit, work coordinately to degrade polyubiquitinated proteins, thereby regulating critical cellular processes such as the cell cycle, signal transduction, and the immune response (StatPearls, 2023). In oncology, particularly in the treatment of multiple myeloma and mantle cell lymphoma, these sites are targeted by proteasome inhibitors to induce proteotoxic stress and subsequent apoptosis in malignant cells that are highly dependent on protein turnover (Moreau et al., 2012). While many first-generation inhibitors primarily target the beta 5 site, newer agents like marizomib are designed to inhibit beta 1 and beta 2 as well, which can enhance therapeutic efficacy and help overcome drug resistance (Miller et al., 2013). Clinical use of drugs targeting these sites requires careful management of side effects such as peripheral neuropathy and hematologic toxicities (NIH/NCI).

Other names

Caspase-like catalytic site (beta 1)Trypsin-like catalytic site (beta 2)20S proteasome beta 1 and beta 2 subunitsPSMB1 and PSMB2Multicatalytic endopeptidase complex subunits beta 1 and 2

Inhibition of the N-terminal threonine active sites within the beta subunits of the 20S proteasome core, leading to the accumulation of polyubiquitinated proteins, induction of the unfolded protein response (UPR), and subsequent apoptosis (Moreau et al., 2012).